[2]
Alzubaidi NH, Chapin HL, Vanderhoof VH, et al. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002; 99: 720-5.
[4]
Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol 2010; 45: 257-79.
[5]
Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Womens Health 2015; 11: 169-82.
[6]
Silva CA, Yamakami LYS, Aikawa NE, et al. Autoimmune primary ovarian insufficiency. Autoimmun Rev 2014; 13: 427-30.
[7]
Nelson LM. Primary ovarian insufficiency. N Engl J Med 2009; 360: 606-14.
[8]
Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil Steril 1995; 64: 740-5.
[9]
van Kasteren YM, Hundscheid RD, Smits AP, et al. Familial idiopathic premature ovarian failure: An overrated and underestimated genetic disease? Hum Reprod 1999; 14: 2455-9.
[10]
Maclaran K, Panay N. Premature ovarian failure. J Fam Plann Reprod Health Care 2011; 37: 35-42.
[11]
Ossewaarde ME, Bots ML, Verbeek ALM, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005; 16: 556-62.
[12]
Wellons M, Ouyang P, Schreiner PJ, et al. Early menopause predicts future coronary heart disease and stroke: The multi-ethnic study of atherosclerosis. Menopause 2012; 19: 1081-7.
[13]
Roeters van Lennep JE, Heida KY, Bots ML, et al. Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23: 178-86.
[14]
Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: The Adventist Health Study. J Clin Epidemiol 1999; 52: 303-7.
[15]
Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality. JAMA Cardiol 2016; 1: 767.
[16]
Tao X-Y, Zuo A-Z, Wang J-Q. Effect of primary ovarian insufficiency and early natural menopause on mortality: A meta-analysis. Climacteric 2016; 19: 27-36.
[17]
Atsma F, Bartelink M-LEL, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis. Menopause 2006; 13: 265-79.
[18]
Løkkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: Influence of hormone therapy. Maturitas 2006; 53: 226-33.
[19]
Van der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347: 714-8.
[20]
Zhao Z, Wang H, Jessup JA, et al. Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol 2014; 306: 628-40.
[21]
Sturdee DW, Collins P, Genazzani AR, et al. Aging, menopause, cardiovascular disease and HRT. International menopause society consensus statement. Climacteric 2009; 12: 368-77.
[22]
Kalantaridou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: Normalization with hormone therapy. J Clin Endocrinol Metab 2004; 89: 3907-13.
[23]
Knauff EAH, Westerveld HE, Goverde AJ, et al. Lipid profile of women with premature ovarian failure. Menopause 2008; 15: 919-23.
[24]
Corrigan EC, Nelson LM, Bakalov VK, et al. Effects of ovarian failure and X-chromosome deletion on body composition and insulin sensitivity in young women. Menopause 2006; 13: 911-6.
[25]
Eshtiaghi R, Esteghamati A, Nakhjavani M, et al. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 2010; 65: 262-6.
[26]
Daan NMP, Muka T, Koster MPH, et al. Cardiovascular risk in women with premature ovarian insufficiency compared to premenopausal women at middle age. J Clin Endocrinol Metab 2016; 101: 3306-15.
[27]
Rocca WA, Grossardt BR, Miller VM, et al. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012; 19: 272-7.
[28]
Jacoby VL, Grady D, Wactawski-Wende J, et al. Oophorectomy vs. ovarian conservation with hysterectomy: Cardiovascular disease, hip fracture, and cancer in the women’s health initiative observational study. Arch Intern Med 2011; 171: 760-8.
[29]
Daan NMP, Jaspers L, Koster MPH, et al. Androgen levels in women with various forms of ovarian dysfunction: Associations with cardiometabolic features. Hum Reprod 2015; 30: 2376-86.
[30]
Bernini GP, Moretti A, Sgró M, et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001; 8: 43-50.
[31]
Stevenson JC. The metabolic basis for the effects of HRT on coronary heart disease. Endocrine 2004; 24: 239-44.
[32]
Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75: 898-915.
[33]
Stevenson JC, Rioux JE, Komer L, et al. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Climacteric 2005; 8: 352-9.
[34]
Stevenson JC, Chines A, Pan K, et al. A pooled analysis of the effects of conjugated estrogens/bazedoxifene on lipid parameters in postmenopausal women from the selective estrogens, menopause, and response to therapy (SMART) trials. J Clin Endocrinol Metab 2015; 100: 2329-38.
[35]
Scarabin P-Y, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.
[36]
Paschou S, Anagnostis P, Vryonidou A, et al. Diabetes and atherosclerosis: Old players in a new field, Osteoporosis. Curr Vasc Pharmacol 2018; 16: 524-7.
[37]
van Der Voort DJM, van Der Weijer PHM, Barentsen R. Early menopause: Increased fracture risk at older age. Osteoporos Int 2003; 14: 525-30.
[38]
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288: 321-33.
[39]
Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: Results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014; 99: 3418-26.
[40]
van der Klift M, de Laet CE, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: The rotterdam study. J Bone Miner Res 2004; 19: 1172-80.
[41]
Baber RJ, Panay N, Fenton A, et al. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19: 109-50.
[43]
van der Stege JG, Groen H, van Zadelhoff SJN, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008; 15: 23-31.
[44]
Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: A systematic review and meta-analysis. J Steroid Biochem Mol Biol 2014; 142: 90-8.
[46]
Nelson LM, Covington SN, Rebar RW. An update: Spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005; 83: 1327-32.
[47]
Bidet M, Bachelot A, Touraine P. Premature ovarian failure: Predictability of intermittent ovarian function and response to ovulation induction agents. Curr Opin Obstet Gynecol 2008; 20: 416-20.
[48]
Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of Parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70: 200-9.
[49]
Soni M, Hogervorst E. Premature ovarian insufficiency and neurological function. Minerva Endocrinol 2014; 39: 189-99.
[50]
Ryan J, Scali J, Carrière I, et al. Impact of a premature menopause on cognitive function in later life. BJOG 2014; 121: 1729-39.
[51]
Mittal M, Savvas M, Narvekar N, et al. A cross-sectional national questionnaire survey assessing the clinical attitudes of members of the British menopause society to the management of women with premature ovarian insufficiency. Post Reprod Health 2014; 20: 90-7.
[52]
Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: Endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; 4CD000402
[53]
Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: A population-based study. J Thromb Haemost 2010; 8: 979-86.
[54]
Rosano GM, Vitale C, Silvestri A, et al. Metabolic and vascular effect of progestins in post-menopausal women: Implications for cardioprotection. Maturitas 2003; 46: 17-29.
[55]
Panay N, Hamoda H, Arya R, et al. British menopause society and women’s health concern. The 2013 British menopause society & women’s health concern recommendations on hormone replacement therapy. Menopause Int 2013; 19: 59-68.
[56]
Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the north American menopause society. Menopause 2008; 15: 584-602.
[57]
Wu X, Cai H, Kallianpur A, et al. Impact of premature ovarian failure on mortality and morbidity among chinese women. PLoS One 2014; 9e89597
[58]
Guttmann H, Weiner Z, Nikolski E, et al. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clin Endocrinol 2001; 54: 159-64.
[59]
Langrish JP, Mills NL, Bath LE, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 2009; 53: 805-11.
[60]
Crofton PM, Evans N, Bath LE, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: Effects on bone mass acquisition and turnover. Clin Endocrinol 2010; 73: 707-14.
[61]
Cartwright B, Robinson J, Seed PT, et al. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: A randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 2016; 101: 3497-505.
[62]
Panay N, Fenton A. Premature ovarian insufficiency: Working towards an international database. Climacteric 2012; 15: 295-6.
180
25
1